Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 3:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 2,099 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Injectable saline Clear all
Not yet recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 )

NCT07526974
View directory record Official record
Conditions
Subcutaneous Fat
Interventions
CBL-514 Injection, 0.9% Sodium Chloride
Drug
Lead sponsor
Caliway Biopharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
11
States / cities
Encinitas, California • Aventura, Florida • Alpharetta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 22, 2026, 3:36 PM EDT
Completed No phase listed Observational

Graded TTCE for Post-Embolization PAVM Monitoring

NCT02936349
View directory record Official record
Conditions
Hereditary Hemorrhagic Telangiectasia (HHT)
Interventions
Transthoracic Contrast Echocardiogram
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 89 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Oct 22, 2026, 3:36 PM EDT
Withdrawn Phase 2 Interventional

Botulinum Toxin Type A for Neuroma Pain

NCT01374191
View directory record Official record
Conditions
Neuroma
Interventions
onabotulinum toxin type-A, placebo, 2nd phase - onabotulinum toxin type-A
Drug · Other
Lead sponsor
Southern Illinois University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 26, 2015 · Synced Oct 22, 2026, 3:36 PM EDT
Completed Phase 1 Interventional

Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks

NCT01405391
View directory record Official record
Conditions
Major Advanced Solid Tumors Other Than Colorectal
Interventions
PM01183
Drug
Lead sponsor
PharmaMar
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Aurora, Colorado • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 15, 2016 · Synced Oct 22, 2026, 3:36 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis

NCT00298272
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
IDEC-C2B8 (rituximab), Placebo, Methotrexate, Etanercept, Adalimumab, Methylprednisolone, Folate
Biological · Drug · Dietary Supplement
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
18
States / cities
Huntsville, Alabama • Paradise Valley, Arizona • Palm Desert, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2015 · Synced Oct 22, 2026, 3:36 PM EDT
Completed Phase 1 Interventional Results available

Endoscopic Ultrasound-guided Ethanol Injection of Pancreatic Cystic Neoplasms

NCT02158039
View directory record Official record
Conditions
Neoplasms, Cystic, Mucinous, and Serous
Interventions
Ethanol, Lidocaine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 22, 2026, 3:36 PM EDT
Completed Not applicable Interventional

Reduction of Radiation Dose and Contrast Use During Cryoballoon Pulmonary Vein Isolation

NCT03786822
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Cryoballoon Pulmonary Vein Isolation - PVI
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 26, 2018 · Synced Oct 22, 2026, 3:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD)

NCT02754830
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
LY3303560 - IV, Saline Solution - IV, LY3303560 - SC
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
30 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2023 · Synced Oct 22, 2026, 3:36 PM EDT
Completed Phase 2 Interventional Results available

Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder

NCT00722553
View directory record Official record
Conditions
Carcinoma, Transitional Cell, Bladder Cancer, Bladder Neoplasm
Interventions
Pralatrexate Injection, Vitamin B12, Folic Acid
Drug · Dietary Supplement
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
4
States / cities
Tucson, Arizona • Atlanta, Georgia • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 22, 2026, 3:36 PM EDT
Completed Phase 2 Interventional

Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM

NCT01658501
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
50 mg PB1023, 70 mg PB1023, 100 mg PB1023, Placebo (0.9% Sodium Chloride), Victoza®, Diet and Exercise, Metformin, Sulfonylurea, Metformin and Sulfonylurea
Drug · Other
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
593 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
93
States / cities
Anniston, Alabama • Birmingham, Alabama • Gulf Shores, Alabama + 90 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Oct 22, 2026, 3:36 PM EDT
Active, not recruiting Phase 4 Interventional

Romosozumab Use to Build Skeletal Integrity

NCT05058976
View directory record Official record
Conditions
Osteoporosis, Osteoporosis, Postmenopausal, Osteoporosis Fracture
Interventions
Romosozumab, Placebo, Zoledronic acid, Calcium and Vitamin D
Drug · Dietary Supplement
Lead sponsor
Susan L. Greenspan
Other
Eligibility
65 Years and older · Female only
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 22, 2026, 3:36 PM EDT
Completed Phase 2 Interventional Results available

Proof of Mechanism Study of GSK2330811 in Diffuse Cutaneous Systemic Sclerosis

NCT03041025
View directory record Official record
Conditions
Scleroderma, Systemic
Interventions
GSK2330811, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
6
States / cities
Los Angeles, California • Stanford, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Oct 22, 2026, 3:36 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Wound Infiltration as Part of an Opioid Free Pain Management Pathway Following Cesarean Delivery

NCT03545516
View directory record Official record
Conditions
Pain, Postoperative, Anesthesia, Local, Opioid Use
Interventions
Bupivacaine, Dexmedetomidine, Placebo
Drug
Lead sponsor
Richmond University Medical Center
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
540 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Staten Island, New York
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 22, 2026, 3:36 PM EDT
Terminated Phase 2 Interventional Results available

Ferric Carboxymaltose to Improve Skeletal Muscle Metabolism in Heart Failure Patients With Functional Iron Deficiency

NCT03218384
View directory record Official record
Conditions
Iron-deficiency
Interventions
Ferric Carboxymaltose, Placebo, 31P MRS/MRI
Drug · Device
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Oct 22, 2026, 3:36 PM EDT
Withdrawn Phase 2 Interventional

Botulinum Toxin Injection With Prostate Brachytherapy

NCT00681148
View directory record Official record
Conditions
Prostate Cancer, Lower Urinary Tract Symptoms, Radioactive Seed Implantation
Interventions
Botox injection, Saline injection
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 21, 2013 · Synced Oct 22, 2026, 3:36 PM EDT
Withdrawn Phase 1 Interventional

Whole Abdomen Radiation in Conjunction With Intraperitoneal Chemotherapy for the Treatment of Small Volume Recurrent Ovarian Carcinoma Limited to the Peritoneal Cavity

NCT00942838
View directory record Official record
Conditions
Recurrent Ovarian Carcinoma
Interventions
Cisplatin, Whole Abdomen Radiotherapy
Drug · Radiation
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 24, 2013 · Synced Oct 22, 2026, 3:36 PM EDT
Recruiting Phase 2 Interventional

IncobotulinumtoxinA for Provoked Vestibulodynia With Overactive Pelvic Floor Muscle Dysfunction

NCT07486830
View directory record Official record
Conditions
Provoked Vestibulodynia
Interventions
Incobotulinum Toxin A, Placebo
Drug
Lead sponsor
Center for Vulvovaginal Disorders
Other
Eligibility
18 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Washington D.C., District of Columbia • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 22, 2026, 3:36 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine

NCT02837575
View directory record Official record
Conditions
Herpes Genitalis
Interventions
VCL-HB01, Phosphate-buffered saline
Biological · Other
Lead sponsor
Vical
Industry
Eligibility
18 Years to 50 Years
Enrollment
261 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
15
States / cities
Birmingham, Alabama • San Diego, California • Hollywood, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Oct 22, 2026, 3:36 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men

NCT02716675
View directory record Official record
Conditions
HIV Infections
Interventions
VRC01, Placebo for VRC01
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years · Male only
Enrollment
2,699 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Oct 22, 2026, 3:36 PM EDT
Completed Phase 2 Interventional Results available

Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease

NCT00498602
View directory record Official record
Conditions
Alzheimer Disease
Interventions
ACC-001 + QS-21, QS-21, Diluent: Phosphate Buffered Saline, ACC-001
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 85 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
27
States / cities
Phoenix, Arizona • Sun City, Arizona • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2016 · Synced Oct 22, 2026, 3:36 PM EDT
Not listed Phase 2 Interventional

MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients

NCT04646603
View directory record Official record
Conditions
COVID-19, ARDS, Human, Stem Cells, Regeneration
Interventions
MRG-001, Placebo
Drug
Lead sponsor
MedRegen LLC
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Oct 22, 2026, 3:36 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours

NCT02683941
View directory record Official record
Conditions
Neuroendocrine Tumors in Lung
Interventions
Lanreotide (Autogel formulation), Placebo, Best Supportive Care
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
14
States / cities
Tucson, Arizona • Los Angeles, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2022 · Synced Oct 22, 2026, 3:36 PM EDT
Completed Phase 3 Interventional Results available

A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence

NCT04994535
View directory record Official record
Conditions
Platysma Prominence
Interventions
OnabotulinumtoxinA, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
20
States / cities
Birmingham, Alabama • Los Angeles, California • Vista, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 22, 2026, 3:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study of an HIV Vaccine in Healthy, HIV Uninfected Adults

NCT02218125
View directory record Official record
Conditions
Healthy
Interventions
MVA Mosaic, Placebo
Biological
Lead sponsor
Crucell Holland BV
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 27, 2018 · Synced Oct 22, 2026, 3:36 PM EDT